In Silico Screening of Phytoconstituents from Hypericum sp. as JAK3 Inhibitors for Autoimmune Disorders

Clicks: 13
ID: 309199
2025
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #12 of 153 articles by views in International Journal of Pharmaceutical Drug Design (IJPDD)

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 153 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Janus kinase (JAK)s has become a viable therapeutic target, for autoimmune and inflammatory diseases. However, its use is complicated by over 50 different cytokines involved in immune responses, potentially leading to adverse consequences. Among JAKs JAK3 has substantial immunomodulatory effects. Indeed, JAK3 emerges as an exceptionally appealing target for therapeutic interventions in autoimmune and inflammatory disorders. Therefore, it is critical to develop specific JAK3 inhibitors. The present investigation utilized Pyrx and to conduct virtual screening and molecular docking analysis on the active components from one of the species of Hypericum i.e. Hypericum perforatum, with the JAK3 receptor. Among the phytoconstituents hypericin, demonstrated an exceptional affinity (-12.4 kcal/mol) for the JAK3 protein. Additionally, hypericin exhibited favorable ADMET properties as predicted by pkCSM and Swiss ADME, supporting its potential as a drug candidate. The findings suggest that hypericin might serve as a viable therapeutic alternative for autoimmune disorders. However, in vivo and in vitro investigations specific to JAK3 are required to validate and extend these results.
Reference Key
imported_1761926632_6904dde89179d Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sukriti Srivastava, Siddhi Srivastava, Mujeeba Rehman, Vipul Agarwal, Rishabh Chaudhary, Arjun Singh Kaushik, Vikas Mishra*
Journal International Journal of Pharmaceutical Drug Design (IJPDD)
Year 2025
DOI
10.62896/ijpdd.2.4.12
URL
https://ijpdd.org/index.php/files/article/view/259
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.